A Device-Based Approach to Type 2 Diabetes: AquaMedical’s Endoscopic Small Bowel Ablation Platform
MedTech Unboxed: Presented by Chamfr
Can a minimally invasive device procedure do more than manage type 2 diabetes symptoms and actually help change the course of the disease? In this episode of MedTech Unboxed, Steve talks with Lloyd about AquaMedical’s endoscopic platform for treating type 2 diabetes through controlled small bowel ablation.
They discuss why current diabetes drugs, including GLP-1 therapies, still leave a major unmet need, and how AquaMedical’s through-the-scope catheter uses hot water vapor and a nitinol basket to deliver a controlled ablation in the small bowel. The conversation explores the clinical logic behind the approach, how it relates to what has been observed in bariatric surgery, and why treating more surface area in the small bowel may be driving stronger metabolic results.
Lloyd also shares early clinical outcomes, including reductions in glucose and hemoglobin A1C, progress in insulin-dependent patients, and the product design advantages of a lower-profile, through-the-scope system that does not require fluoroscopy. The episode also covers FDA progress, IDE approval, competitive differentiation, and the company’s next milestones as it moves into US clinical studies. For medtech professionals in GI, endoscopy, metabolic disease, catheter design, and device innovation, this is a fascinating look at a novel platform aimed at one of healthcare’s biggest problems.
Loading